GleamWall
中文EN

TXMD TherapeuticsMD, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 25743 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY33.9%
TTM net income YoY-59.6%
TTM EPS YoY-50.0%
Revenue 3-yr CAGR24.3%
Net income 3-yr CAGR-87.9%

Margins

Gross margin—
Operating margin-95.3%
Net margin3.3%
FCF margin—
EBITDA margin-85.1%

Returns

ROE0.4%
ROA0.3%
ROIC (approx.)-19.0%
Asset turnover0.10x

Leverage & solvency

Liabilities / assets27.2%
Debt / equity0.00x
Current ratio3.32x
Interest coverage—

Cash quality & payout

Operating cash flow / net income27.59x
Accruals ratio-8.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$3.02M$1.76M
SG&A expense$6.85M$6.10M
Operating income-$4.39M-$6.11M
Interest expense$8,000$10,000
Pretax income-$653,000-$2.34M
Income tax—-$31,000
Net income-$569,000-$2.18M
EBITDA-$4.01M-$5.60M
EPS (basic)-0.05-0.19
EPS (diluted)-0.05-0.19
Weighted avg. shares (diluted)11.57M11.53M
Balance sheet
Cash & equivalents$7.48M$5.06M
Current assets$14.45M$12.26M
Intangibles$3.76M$4.32M
Total assets$37.66M$38.82M
Current liabilities$4.79M$5.17M
Total liabilities$10.78M$11.45M
Shareholders' equity$26.88M$27.37M
Shares outstanding11.57M11.53M
Cash flow statement
Operating cash flow$2.45M$1.17M
Depreciation & amortization$384,000$509,000
Stock-based compensation$75,000$264,000

Free plan shows the latest 2 periods; Pro shows all 16 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.